Shots:

• Baxter acquires Cheetah Medical for up to $230M including $190M as up front with $40M as clinical & development milestones. The acquisition is expected to close in Q4’19
• The focus of the acquisition is to expand Baxter’s specialized patient monitoring portfolio with the addition of Cheetah’s non-invasive hemodynamic monitoring technologies including Starling SV system used for fluid management and enhance Baxter’s leadership in medication delivery and critical care
• Cheetah’s acquisition supports Baxter's efforts to enable personalized therapy and help to eliminate preventable harm across the globe. Cheetah’s technologies are designed to be used in an operating room and emergency department settings providing assessments of fluid responsiveness

Click here to­ read full press release/ article | Ref: Baxter | Image: Cheetah Medical